NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
02 Octobre 2023 - 3:00PM
NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been
selected as a Proud Sponsor of the National Fibromyalgia
Association (NFA).
As a Proud Sponsor NeuroMetrix will support the NFA’s mission to
provide education, support, and advocacy for people living with
fibromyalgia and their loved ones. “We are delighted to work with
the National Fibromyalgia Association to further our mutual
commitment to the fibromyalgia community,” said Shai N. Gozani,
M.D., Ph.D., CEO of NeuroMetrix. “This partnership aligns to our
mission to empower individuals to regain control of their lives and
reduce the burden of chronic pain. We look forward to working with
the NFA to get the word out on Quell® Fibromyalgia and other safe
and effective treatment options for those affected by
fibromyalgia.”
Lynne Matallana, President and Founder of the National
Fibromyalgia Association, added, “We are grateful to NeuroMetrix
for their support in our mission to improve the lives of people
with fibromyalgia. This partnership will enable us to continue our
vital work, offering hope and assistance to those who need it
most.”
Quell Fibromyalgia Indications
Quell Fibromyalgia is a transcutaneous electrical nerve
stimulation (TENS) device indicated as an aid for reducing the
symptoms of fibromyalgia in adults with high pain sensitivity. The
device may be used during sleep.
LimitationsThe sale, distribution, and use of Quell Fibromyalgia
is restricted to prescription use in accordance with 21 CFR
801.109. The Product labeling should be reviewed for a complete
list of contraindications, precautions and warnings. For more
information visit QuellFibromyalgia.com.
About the National Fibromyalgia Association
The National Fibromyalgia Association is a non-profit
organization dedicated to improving the quality of life for people
with fibromyalgia. The NFA provides support, education, advocacy,
and research initiatives to empower individuals and families
affected by fibromyalgia while promoting greater awareness of this
debilitating condition.
About NeuroMetrix
NeuroMetrix is a commercial stage healthcare company that
develops and commercializes neurotechnology devices to address
unmet needs in the chronic pain and diabetes markets. The Company's
products are wearable or hand-held medical devices enabled by
proprietary consumables and software solutions that include mobile
apps, enterprise software and cloud-based systems. The Company has
two commercial brands. Quell® is a wearable neuromodulation
platform. DPNCheck® is a point-of-care screening test for
peripheral neuropathy. For more information,
visit www.neurometrix.com.
Source: NeuroMetrix, Inc.
Thomas T. HigginsSVP and Chief Financial
Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
NeuroMetrix (NASDAQ:NURO)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024